Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)
Clinical trial NCT02835690 · COMPLETED
Trial details
- NCT number
- NCT02835690
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-08-04
- Primary completion
- 2017-09-19
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.